OpenRx Open Medications Explorer
© 2026 OpenRx · public-domain U.S. government data
On this page

Zimeta®

Dipyrone

Veterinary NADA Approved 21 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Zimeta®
Active ingredient
Dipyrone
Application type
NADA
Sponsor
Dechra Veterinary Products LLC
Applications on record
1
First published
July 14, 2026

Adverse event reports

Source: openFDA VeDDRA
21
Reports mentioning this ingredient
January 4, 2017 – January 26, 2026
9
Classified serious
per reporter assessment
0
Lack of expected efficacy
resistance signal
1
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “DIPYRONE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Color, Abnormal 4
Appearance, Abnormal 4
Injection site swelling 2
Containers, Damaged 2
Abnormal breathing 1
Incorrect route of drug administration 1
Product problem 1
Contamination, Foreign Object 1
Death 1
Containers, Leaking 1
Containers, Abnormal 1

Species affected

Source: openFDA VeDDRA
Dog 6 Horse 6 Cat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient